Kikawa Y, Kotake T, Tsuyuki S, Kang Y, et al. Effectiveness of eribulin as first-line or second-line chemotherapy for HER2-negative hormone-resistant advanced or metastatic breast cancer: findings from the multi-institutional, prospective, observational KBCRN A001: E-SPEC study. Breast Cancer 2022 Apr 23. pii: 10.1007/s12282-022-01357.
PMID: 35460066